Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 8/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | SGK1 | O00141 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25933236 | 0.89 | PDPK1 (0.49) | PDPK1FGFR1JAK2SGK1AURKA | |
| SCHEMBL24137844 | 0.87 | MKNK1 (0.58) | PDPK1JAK2SGK1MKNK1MKNK2 | |
| SCHEMBL24137787 | 0.87 | JAK2 (0.61) | PDPK1FGFR1JAK2SGK1AURKA | |
| SCHEMBL24137919 | 0.86 | MKNK1 (0.57) | PDPK1JAK2SGK1MKNK1MKNK2 | |
| SCHEMBL24137495 | 0.86 | PRKACA (0.53) | PDPK1FGFR1JAK2 | |
| SCHEMBL24137548 | 0.86 | MKNK1 (0.59) | PDPK1JAK2SGK1AURKAAURKB | |
| SCHEMBL25933239 | 0.82 | ABL1 (0.54) | PDPK1JAK2SGK1AURKATGFBR1 | |
| SCHEMBL24137502 | 0.80 | JAK2 (0.48) | PDPK1JAK2SGK1AURKATGFBR1 | |
| SCHEMBL24137503 | 0.80 | MAP2K4 (0.55) | PDPK1JAK2SGK1AURKATGFBR1 | |
| SCHEMBL24137497 | 0.80 | MAP2K4 (0.54) | PDPK1FGFR1JAK2AURKATGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | PACSIN2, MAP3K20, PHKG1 | PDPK1 123/4885FGFR1 600/4885JAK2 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.